BridgeBio Oncology Therapeutics

Company snapshot

BBOT (BridgeBio Oncology Therapeutics) is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BBOT completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most

• 1 approved product(s) across US/EU regulatory metadata.
• 34 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for BridgeBio Oncology Therapeutics. Not investment advice.

• Peer + 0 momentum

  BEONE MEDICINES AUS

  TA overlap score 40

• Peer + 0 momentum

  BioMarin Pharmaceutical Australia

  TA overlap score 38.2

Recent activity

Latest pipeline, patent, and corporate events for BridgeBio Oncology Therapeutics.

1. Jun 8, 2026 Clinical update

   Infigratinib — Phase 3

2. Jun 8, 2026 Clinical update

   Infigratinib is provided as a single dose of minitablets for oral administration — Phase 2

3. Jun 8, 2026 Clinical update

   Infigratinib — Phase 2

4. Jun 8, 2026 Clinical update

   Infigratinib — Phase 1

5. Jun 8, 2026 Clinical update

   Infigratinib — Phase 1

View all clinical trial activity →

• What is BridgeBio Oncology Therapeutics?

  BridgeBio Oncology Therapeutics is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker BBOT. Primary therapeutic focus areas include Achondroplasia, Amyloid Cardiomyopathy, Transthyretin-Related, Transthyretin-Related (ATTR) Familial Am

• Is BridgeBio Oncology Therapeutics publicly traded?

  Yes. BridgeBio Oncology Therapeutics is listed with ticker BBOT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does BridgeBio Oncology Therapeutics develop or market?

  We link 14 drug profile(s) where BridgeBio Oncology Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bridgebio-oncology-therapeutics#company-drugs.

• What are the latest developments for BridgeBio Oncology Therapeutics?

  In the last 12 months our linked public records show 34 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does BridgeBio Oncology Therapeutics focus on?

  BridgeBio Oncology Therapeutics focuses on Achondroplasia, Amyloid Cardiomyopathy, Transthyretin-Related, Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy based on our analysis of their pipeline programs and drug development activities.